Express2

DEVICE2 trials

Sponsors

Boston Scientific Corporation

Conditions

Coronary Artery DiseaseCoronary Stenosis

Phase 2

Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stents to Treat De Novo Coronary Lesions

CompletedNCT00301522

Boston Scientific CorporationCoronary Stenosis

Start: 2003-02-28End: 2009-04-30Updated: 2010-08-06

Phase 3

A Study of the TAXUS Liberté Stent for the Treatment of de Novo Coronary Artery Lesions in Small Vessels

CompletedNCT00371748

Boston Scientific CorporationCoronary Artery Disease

Start: 2005-02-28End: 2011-04-30Updated: 2012-02-02

Related Papers

Impact of drug-eluting stents on distal vessels.

2012-04-108 citations

Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials.

2009-12-01144 citations

TAXUS Liberté attenuates the risk of restenosis in patients with medically treated diabetes mellitus: results from the TAXUS ATLAS program.

2009-03-0124 citations

Reduced risk of restenosis in small vessels and reduced risk of myocardial infarction in long lesions with the new thin-strut TAXUS Liberté stent: 1-year results from the TAXUS ATLAS program.

2008-12-0150 citations